(E)-1,3,7-trimethyl-8-(4-chlorostyryl)xanthine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (E)-1,3,7-trimethyl-8-(4-chlorostyryl)xanthine
• 英文别名: 8-(13-Chlorostyryl) caffeine；8-[(E)-2-(4-chlorophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione
• 化学式: C₁₆H₁₅ClN₄O₂
• 分子量: 330.774
• InChiKey: RQLGXOPACNRPQG-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对氯肉桂酸 在 盐酸 、 potassium carbonate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (E)-1,3,7-trimethyl-8-(4-chlorostyryl)xanthine
  参考文献：
  名称：

  选定的C8取代的黄嘌呤的腺苷A 2A拮抗特性

  摘要：

  腺苷A 2A受体被认为是开发帕金森氏病新疗法的重要靶标。为此目的，几种A 2A受体拮抗剂已经进入临床试验，许多研究小组已经启动了开发A 2A受体拮抗剂的计划。大多数A 2A受体拮抗剂属于两个不同的化学类别，即黄嘌呤衍生物和氨基取代的杂环化合物。为了发现高亲和力的A 2A受体拮抗剂并通过黄嘌呤类化合物进一步探索A 2A拮抗作用的构效关系（SAR），本研究对A 2A进行了研究。系列（E）-8-苯乙烯基黄嘌呤，8-（苯氧基甲基）黄嘌呤和8-（3-苯基丙基）黄嘌呤的拮抗特性。结果证明，在这些系列中，（E）-8-苯乙烯基黄嘌呤具有最高的结合亲和力和最强的同系物，（E）-1,3-二乙基-7-甲基-8-[（3-三氟甲基）苯乙烯基]黄嘌呤，表现出ķ我11.9 NM的值。该化合物还有效逆转氟哌啶醇诱导的大鼠僵直症，提供证据表明它实际上是A 2A受体拮抗剂。通过发现8-（苯氧甲基）黄嘌呤和8-（3-苯丙基）黄嘌呤均不显示出对A

  DOI：

  10.1016/j.bioorg.2013.06.006

文献信息

• Dehydrogenative Heck coupling of biologically relevant N-heteroarenes with alkenes: discovery of fluorescent core frameworks
  作者：Yumin Huang、Feijie Song、Zhen Wang、Peihua Xi、Ningjie Wu、Zhigang Wang、Jingbo Lan、Jingsong You

  DOI：10.1039/c2cc17557f

  日期：——

  A Pd/Cu-catalyzed dehydrogenative Heck coupling is established that allows direct alkenylation of various biologically relevant N-heteroarenes with alkenes. The resulting π-extended alkenylated N-heteroarenes exhibit interesting fluorescent properties and have proven to be potentially useful fluorescent probes for bioimaging.

  通过 Pd/Cu 催化的脱氢 Heck 偶联，可使各种生物相关的 N-teroarenes 与烯烃直接发生烯基化反应。由此产生的π-扩展烯基化 N-heteroarenes 显示出有趣的荧光特性，并被证明可能是用于生物成像的有用荧光探针。
• Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)
  作者：Nevil Vlok、Sarel F. Malan、Neal Castagnoli、Jacobus J. Bergh、Jacobus P. Petzer

  DOI：10.1016/j.bmc.2006.01.011

  日期：2006.5

  The adenosine A(2A) receptor has emerged as a possible target for the treatment of Parkinson's disease (PD). Evidence suggests that antagonism of the A(2A) receptor not only improves the symptoms of the disease but may also protect against the underlying degenerative processes. We have recently reported that several known adenosine A(2A) receptor antagonists (A(2A) antagonists) also are moderate to very potent inhibitors of monoamine oxidase B (MAO-B). The most potent among these was (E)-8-(3-chlorostyryl)caffeine (CSC), a compound frequently used when examining the in vivo pharmacological effects of A(2A) antagonists. Since MAO-B inhibitors are also thought to possess antiparkinsonian properties, dual targeting drugs that block both MAO-B and A(2A) receptors may have enhanced therapeutic potential in the treatment of PD. In this study, we prepared selected analogues of CSC in an attempt to examine specific structural features that may be important for potent MAO-B inhibition. The results of a SAR study established that the potency of MAO-B inhibition by (E)-8-styrylcaffeinyl analogues depends upon the van der Waals volume (V-w), lipophilicity (pi), and the Hammett constant (sigma(m)) of the substituents attached to C-3 of the phenyl ring of the styryl moiety. Potency also varies with substituents attached to C-4 with bulkiness (V-w) and lipophilicity (pi) being the principal substituent descriptors. (c) 2006 Elsevier Ltd. All rights reserved.
• Synthesis of (<i>E</i>)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A_2A Antagonists/MAO-B Inhibitors
  作者：Silvia Rivara、Giovanni Piersanti、Francesca Bartoccini、Giuseppe Diamantini、Daniele Pala、Teresa Riccioni、Maria Antonietta Stasi、Walter Cabri、Franco Borsini、Marco Mor、Giorgio Tarzia、Patrizia Minetti

  DOI：10.1021/jm301686s

  日期：2013.2.14

  A systematic modification of the caffeinyl core and substituents of the reference compound (E)-8-(3-chlorostyryl)caffeine led to the 9-deazaxanthine derivative (E)-6-(4-chlorostyryl)-1,3,5,=trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f), which acts as a dual human A(2a) antagonist/MAO-B inhibitor (K-i(A(2A)) = 260 nM; IC50(MAO-B) = 200 nM; IC50(MAO-A) = 10 mu M) and dose dependently counteracts haloperidol-induced catalepsy in mice from 30 mg/kg by the oral route. The compound is the best balanced A(2A) antagonist/MAO-B inhibitor reported to date, and it could be considered as a new lead in the field of anti-Parkinson's agents. A number of analogues of 17f were synthesized and qualitative SARs are discussed. Two analogues of 17f, namely 18b and 19a, inhibit MAO-B with IC50 of 68 and 48 nM, respectively, being 5-7-fold more potent than the prototypical MAO-B inhibitor deprenyl (IC50 = 334 nM).